Compare CBRS & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBRS | IQV |
|---|---|---|
| Founded | 2016 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Semiconductors | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0B | 43.1B |
| IPO Year | 2024 | 2013 |
| Metric | CBRS | IQV |
|---|---|---|
| Price | $115.45 | $274.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 20 |
| Target Price | $282.55 | ★ $309.76 |
| AVG Volume (30 Days) | ★ 8.8M | 1.1M |
| Earning Date | 11-12-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 5.24 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $73.94 | $7.10 |
| Revenue Next Year | $232.73 | $6.36 |
| P/E Ratio | ★ N/A | $53.27 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $105.36 | $154.50 |
| 52 Week High | $265.63 | $284.50 |
| Indicator | CBRS | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 33.24 | 56.23 |
| Support Level | N/A | $252.55 |
| Resistance Level | $221.60 | $274.49 |
| Average True Range (ATR) | 9.64 | 9.16 |
| MACD | -0.87 | 0.63 |
| Stochastic Oscillator | 18.07 | 62.82 |
Cerebras Systems Inc is an AI company. It designs the world's fastest AI infrastructure for training and inference. The company builds the world's largest semiconductor as well as the AI systems to power, cool, and feed the processors data. It develops software to link these systems together into industry-leading supercomputers that are simple to use even for the most complicated AI work, using familiar ML frameworks like PyTorch. Customers use its supercomputers to train industry-leading models. The company uses these supercomputers to run inference at speeds unobtainable from alternative commercial technologies. It delivers these AI capabilities to its customers on-premise and via the cloud. The company generates the majority of its revenue from the USA.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.